Covid 19 Vaccine Latest News Update: Covid 19 Vaccine Human Trials Begins

By | May 5, 2020

Covid 19 Vaccine Latest News Update: Covid 19 Vaccine Human Trials Begins:

covid 19 vaccine status

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID‑19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine. In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), the causative virus, to become available in less than 18 months.

The Coalition for Epidemic Preparedness Innovations (CEPI) – which is organizing a US$2 billion worldwide fund for rapid investment and development of vaccine candidate – indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021.

On 4 May 2020, the WHO organized a telethon to raise US$8 billion from forty countries to support rapid development of vaccines to prevent COVID-19 infections.

In April 2020, 115 vaccine candidates were in development,with five having been initiated in phase I–II safety and efficacy studies in human subjects, and six in phase I trials.

Covid 19 Vaccine in China:

The government is providing low-rate loans to vaccine developers through its central bank, and enabled land transfers to build production plants. There are nine Chinese COVID-19 vaccines in development, involving 1,000 scientists and Chinese research institutes and military hospitals.Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing the most promising vaccine candidates, while prioritizing rapid evidence of efficacy over safety.

Covid 19 Vaccine in UK:

In April, the UK government formed a COVID-19 vaccine taskforce to stimulate British efforts for rapidly developing a vaccine through collaborations of industry, universities, and government agencies across the vaccine development pipeline, including for clinical trial placement at UK hospitals, regulations for approval, and eventual manufacturing.The vaccine development initiatives at the University of Oxford and Imperial College of London were financed with £44 million in April.

Covid 19 Vaccine in United States:

Biomedical Advanced Research and Development Authority (BARDA) a federal agency that funds disease-fighting technology, announced investments of nearly US$1 billion to support American COVID-19 vaccine development, and preparation for manufacturing the most promising candidates. BARDA made a US$483 million investment in the vaccine developer, Moderna and its partner, Johnson & Johnson.

BARDA has an additional US$4 billion to spend on vaccine development, and will have roles in other American investment for development of six to eight vaccine candidates to be in clinical studies over 2020-21 by companies, such as Sanofi Pasteur and Regeneron.

In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID‑19.Major platform targets advanced into phase I safety studies include:

  • nucleic acid (DNA and RNA) (phase I developer and vaccine candidate: Moderna, mRNA-1273)
  • viral vector (phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
  • virus-like particle involved in DNA replication (phase I developer and vaccine candidate: Shenzhen Geno-Immune Medical Institute, LV-SMENP)

According to CEPI, the platforms based on DNA or messenger RNA offer considerable promise to alter COVID‑19 antigen functions for strong immune responses, and can be rapidly assessed, refined for long-term stability, and prepared for large-scale production capacity.Other platforms being developed in 2020 focus on peptides, recombinant proteins, live attenuated viruses, and inactivated viruses.

As of early May 2020, global health organizations estimated that it could cost US $20–25 billion to manufacture and distribute vaccines that can reach most of the world’s population.This would be in addition to the costs of vaccine development.

All State Wise



Police Jobs

83652 Apply Now

Govt Jobs

76522 Apply Now

PSU Jobs

65435 Apply Now

Bank Jobs

15365 Apply Now

Engineering Jobs

77065 Apply Now

Army Jobs

54568 Apply Now

Teaching Jobs

35265 Apply Now

High Court Jobs

2351 Apply Now

Insurance Jobs

1254 Apply Now

Postal Jobs

1562 Apply Now

Private Sector Jobs

45852 Apply Now

Transport Jobs

25251 Apply Now

Sarkari Naukri Jobs

78652 Apply Now

Leave a Reply

Your email address will not be published. Required fields are marked *